Amicus (FOLD) Banks on Galafold, High Dependence a Concern

Amicus Therapeutics, Inc.'s (FOLD) lead marketed drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has witnessed a strong sales uptake driven by continued demand. Sales of Galafold have been rising consistently over the past years. In the first six months of 2024, the drug generated sales worth $210.2 million, which increased 17% year over year at a constant currency basis. Galafold is currently approv ...